Estrella Immunopharma (ESLA) News Today $0.98 +0.26 (+35.53%) Closing price 10/23/2026 04:00 PM EasternExtended Trading$0.97 -0.02 (-1.52%) As of 10/23/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share News and Trends Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings Estrella Immunopharma Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2026 September 2026 August 2026 July 2026 June 2026 May 2026 April 2026 March 2026 February 2026 January 2026 December 2025 November 2025 October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 Time Period More filters Fewer filters Done Estrella Immunopharma (ESLA) stock soars 18%: what's driving the surgeOctober 22 at 7:19 AM | msn.comEstrella Immunopharma, Inc. Activates Intermountain Health LDS Hospital As Fifth Clinical Site For Phase I/II STARLIGHT-1 Trial In B-Cell Non-Hodgkin?s LymphomaOctober 16, 2026 | marketscreener.comMEstrella Immunopharma Treats First Patient with Two EB103 Infusions in STARLIGHT-1 Dose-Expansion PhaseOctober 15, 2026 | finance.yahoo.comEstrella Immunopharma Activates Intermountain Health LDS Hospital as Fifth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s LymphomaOctober 14, 2026 | finance.yahoo.comEstrella Immunopharma Activates Intermountain Health LDS Hospital as Fifth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin's LymphomaOctober 14, 2026 | businesswire.comEstrella’s EB103 Lymphoma Trial Advances, Keeping High-Risk Cell Therapy Hopes AliveOctober 1, 2026 | tipranks.comESLA: First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 TrialAugust 26, 2026 | finance.yahoo.comEstrella Immunopharma Activates University Hospitals Cleveland Medical Center as Fourth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s LymphomaAugust 11, 2026 | finance.yahoo.comEstrella Immunopharma Activates Baylor Scott & White Research Institute as Second Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s LymphomaJuly 29, 2026 | finance.yahoo.comEstrella Immunopharma Announces First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial and Reports Durable Response Rate in Advanced B-Cell Non-Hodgkin’s LymphomaJuly 24, 2026 | finance.yahoo.comEstrella Immunopharma Announces First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial and Reports Durable Response Rate in Advanced B-Cell Non-Hodgkin's LymphomaJuly 24, 2026 | businesswire.comESLA: Can Next-Generation CAR-T Therapy Improve Disease Control in Extranodal Lymphoma?July 14, 2026 | finance.yahoo.comEstrella Immunopharma Announces Appointment of Hong Zhang as Chairperson and Board MemberJuly 7, 2026 | businesswire.comEstrella Immunopharma Shareholders Ratify 2026 Auditor AppointmentJune 30, 2026 | tipranks.comEstrella Immunopharma Inc.June 9, 2026 | barrons.comEstrella Immunopharma to Participate in the D. Boral Capital Global ConferenceMay 5, 2026 | businesswire.comEstrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Initiating Coverage with a Valuation of $12.00/Share from Zacks Small-Cap ResearchMarch 23, 2026 | finance.yahoo.comESLA: 100% CR Rate in Phase 1/2 Trial of EB103 in Aggressive B Cell NHLFebruary 10, 2026 | msn.comEstrella Immunopharma (ESLA) price target decreased by 50.00% to 8.16February 4, 2026 | msn.comEstrella Immunopharma Announces Late-Breaking Oral Presentation of Phase 1 STARLIGHT-1 Data for EB103 at the 2026 Tandem Meetings of ASTCT® & CIBMTR®February 3, 2026 | finance.yahoo.comEstrella Immunopharma Receives Nasdaq Non-Compliance NoticeJanuary 15, 2026 | theglobeandmail.comEstrella Immunopharma Announces Closing of $8.0 Million Registered Direct Offering and Concurrent Private PlacementJanuary 6, 2026 | businesswire.comEstrella Immunopharma stock falls after announcing $8 million offeringJanuary 5, 2026 | in.investing.comEstrella Immunopharma, Inc. Announces $8.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq RulesJanuary 5, 2026 | finance.yahoo.comEstrella Immunopharma files to sell 2.54M shares of common stock for holdersDecember 22, 2025 | msn.comEstrella Immunopharma shares gain as CD19 cancer therapy progresses into phase IIDecember 4, 2025 | msn.comEstrella Immunopharma stock rises as cancer therapy advances to Phase IIDecember 4, 2025 | investing.comEstrella Immunopharma Achieves Milestone in STARLIGHT-1 TrialNovember 7, 2025 | msn.comEstrella Immunopharma stock soars after 100% complete response rate in trialNovember 4, 2025 | in.investing.comEstrella Immunopharma Regains Compliance with Nasdaq Listing RequirementsOctober 6, 2025 | finance.yahoo.comEstrella Immunopharma Regains Nasdaq ComplianceSeptember 29, 2025 | tipranks.comIs Estrella Immunopharma (NASDAQ:ESLA) In A Good Position To Deliver On Growth Plans?August 14, 2025 | finance.yahoo.comEstrella Immunopharma Announces Activation of Additional Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s LymphomaJune 5, 2025 | finance.yahoo.comEstrella Immunopharma to sell 2.333M shares at $1.50 in private placementJune 4, 2025 | msn.comEstrella Immunopharma Announces Approximately $3.35 Million Private Placement Equity FinancingJune 4, 2025 | finance.yahoo.comESLA Estrella Immunopharma, Inc.May 30, 2025 | seekingalpha.comEstrella Immunopharma, Inc. (ESLA) Doses First Patient in Higher-Dose Cohort of EB103 Phase I/II TrialMay 29, 2025 | msn.comEstrella Immunopharma Initiates Second Cohort and Doses First Patient in STARLIGHT-1 Trial of EB103 in Advanced B-Cell Non-Hodgkin’s LymphomasMay 29, 2025 | finance.yahoo.comEstrella Immunopharma Initiates Second Cohort and Doses First Patient in STARLIGHT-1 Trial of EB103 in Advanced B-Cell Non-Hodgkin's LymphomasMay 29, 2025 | businesswire.comEstrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Buy Rating With a Price Target of $14.00 From CB Capital PartnersMarch 5, 2025 | finance.yahoo.comEstrella Immunopharma completes first dose cohort in STARLIGHT trialFebruary 21, 2025 | markets.businessinsider.comEstrella Immunopharma Completes First Dose Cohort in STARLIGHT-1 Trial and Receives Approval to Initiate Higher Dose CohortFebruary 21, 2025 | businesswire.comEstrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) Receives Buy Rating with a 12-Month Price Target of $16.00 from D. Boral CapitalFebruary 19, 2025 | businesswire.comD. Boral Capital Initiates Coverage of Estrella Immunopharma (ESLA) with Buy RecommendationFebruary 19, 2025 | msn.comSpotlight On US Penny Stocks: Estrella Immunopharma And Two Others To ConsiderNovember 19, 2024 | uk.finance.yahoo.comEstrella Immunopharma (NASDAQ:ESLA) Stock, Short Interest ReportOctober 11, 2024 | benzinga.comEstrella Immunopharma (NASDAQ:ESLA) Stock Quotes, Forecast and News SummaryOctober 11, 2024 | benzinga.comEstrella Immunopharma Shares Rise on Lymphoma Patient's Treatment ResponseSeptember 28, 2024 | marketwatch.comEstrella Immunopharma Achieves Complete Response in First Patient Treated with CD19- Redirected ARTEMIS® T-cellsSeptember 27, 2024 | finance.yahoo.comEstrella Immunopharma, Inc. (ESLAW)August 24, 2024 | uk.finance.yahoo.com Estrella Immunopharma Media Mentions By Week Estrella Immunopharma Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ESLA News Sentiment▼0.000.47▲Average Healthcare News Sentiment Estrella Immunopharma News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ESLA Articles This Week▼11▲ESLA Articles Average Week Estrella Immunopharma Trends on MarketBeatThis week vs. last weekSearches1Page Views1,409-12% Get Estrella Immunopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ESLA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Fractyl Health News Today Kalaris Therapeutics News Today MiNK Therapeutics News Today Black Hawk Acquisition News Today Mereo BioPharma Group News Today Caribou Biosciences News Today iBio News Today Yarrow Bioscience News Today Werewolf Therapeutics News Today ImageneBio News Today News and Trends Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas MarketBeat tracks news from more than one hundred trusted media outlets in real time, with the most recent headline for Estrella Immunopharma dated 10/22/2026. From Our PartnersWhy tech stocks are deadAI skeptics see dot-com era warning signs, and they have a point. But the real opportunity may not be in the b...Porter & Company | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredElon Musk’s One Stock Retirement PlanStanley Druckenmiller once said you don't get rich diversifying into 50 mediocre assets - you get rich finding...Brownstone Research | SponsoredSpaceX is worth trillions. This one's $14.It is not SpaceX, Tesla, Starlink, or Neuralink. But Elon's rocket company shows up in this stock's paperwork,...Behind the Markets | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | SponsoredAsk a 20 Year Trading Pro Your Stock Questions Live for 5Ross Givens, a market analyst with over 20 years on Wall Street, goes live every Monday at 9 AM ET to break do...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Estrella Immunopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Estrella Immunopharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
